A 25-kDa cryptococcal deacetylase (d25) was found here to induce cell proliferation, as well as secretion of interleukin 2 and gamma interferon, but not interleukin 4, in spleen cells from d25-immunized or Cryptococcus neoformans-infected mice. The gamma interferon, but not the interleukin 2, response was required for the protective activities of d25 immunization in a murine cryptococcosis model.
The encapsulated fungus Cryptococcus (Filobasidiella) neoformans is an opportunistic pathogen that often infects patients with immune defects, although cryptococcosis has been reported also in individuals with an intact immune system (12, 22) . Cryptococcal infections are particularly frequent in AIDS patients, often requiring lifelong suppressive therapy to prevent a relapse (19) . Nevertheless, conventional antifungal therapy has toxic side effects, and survivors may progress to fatal disseminated disease despite long-term treatment (24) . These observations indicate the need to develop alternative strategies to control cryptococcosis, including active, passive, or adoptive immunotherapy. Type 1 cytokines, such as interleukin 12 (IL-12) and gamma interferon (IFN-␥), are necessary for the development of immune-protective responses (4, 7, 20) . In contrast, type 2 cytokines, such as interleukin 4 (IL-4) and interleukin 5, are not protective and may be responsible for destructive lung pathology (11, 13) . While many studies have focused on capsular glucuronoxylomannan, the main virulence factor of C. neoformans, little is known of protein antigens capable of inducing cell-mediated immunity (1, 21) . At least four cryptococcal proteins with T-cell-stimulating properties have been identified, and the corresponding genes have been cloned (2, 10, 15, 18) . Two of them, with respective molecular masses of 98 and 25 kDa, have a polysaccharide deacetylase domain (2, 15) . Immunization with the 25-kDa deacetylase (d25) was shown to protect mice from lethal experimental cryptococcosis (2) .
The present study was undertaken to assess the ability of d25 to produce T1-type responses, as measured by lymphocyte proliferation and cytokine production, and to assess the role of such responses in the protective activities of d25 immunization. Mice used in this study were housed under specific-pathogenfree conditions in enclosed filter top cages of the Department of Pathology and Experimental Microbiology of the University of Messina (Messina, Italy). The mice were fed clean food and water ad libitum. All of the procedures described in this work were in agreement with the guidelines of the National Institute of Health for handling of laboratory animals. The studies performed here have been approved by relevant national and institutional committees.
Recombinant and natural d25 (rd25 and nd25, respectively) were produced and purified as previously described (2) . Endotoxin was removed from rd25 preparations using repeated treatments with polymyxin-agarose beads (Bio-Rad Laboratories, Milan, Italy), according to the instructions of the manufacturer. Endotoxin concentration in rd25 or nd25 was Ͻ50 pg/mg as assessed by a Limulus amebocyte lysate assay kit (Associates of Cape Cod Inc.; distributed by PBI International, Milan, Italy). A group of BALB/c mice was infected intravenously (i.v.) with a sublethal dose (2.5 ϫ 10 3 CFU) of the highly virulent C. neoformans H99 strain (ATCC 208821, obtained from the American Type Culture Collection, Manassas, Va.), grown in a synthetic medium (3) to mid-log phase. Mice from another group were immunized subcutaneously (s.c.) with 0.2 ml of a water in oil emulsion containing rd25 (100 g) in complete Freund's adjuvant (CFA) (Sigma, Milan, Italy). Spleens were removed aseptically from these animals at the indicated times. Spleen cells were washed three times in phosphate-buffered saline (PBS) (0.01 M phosphate, 0.15 M NaCl [pH 7.4]) and resuspended in a culture medium containing RPMI 1640, 5% fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, penicillin (100 U/ml), and streptomycin (100 g/ml) (all from Invitrogen, Life Technologies, San Giuliano Milanese, Italy) and 5 ϫ 10 Ϫ3 M 2-mercaptoethanol (Sigma). Cells were incubated at 37°C in 5% CO 2 in the presence or absence of stimuli in the flatbottom wells of 96-well plastic plates (Nunc; distributed by Mascia Brunelli, Milan, Italy). Eighteen hours before the end of each incubation, 1 Ci of tritiated thymidine ([ 3 H]TdR; ICN, Milan, Italy) was added. At the end of the incubation period, the cells were collected onto filter paper using a cell harvester (PBI International). The dried filters were counted in a liquid scintillation ␤-counter (Beckman, Milan, Italy), and the results were expressed as mean counts per minute Ϯ the standard error of the mean (SEM) of triplicate samples. Initial experiments, performed in order to determine the optimal conditions required for splenocyte proliferation, showed that the rd25 antigen was able to induce lymphoproliferation in splenocytes, at concentrations between 2.5 and 50 g/ml and at any time point after immunization or infection (7, 14 , and 28 days) (Fig. 1) . In contrast, splenocytes from mice injected with PBS in CFA did not proliferate (Fig. 1 ). Various numbers of splenocytes were assayed in order to determine the optimal conditions for proliferation. A significant response was achieved when greater than 4 ϫ 10 5 cells/well were present, while a maximum peak of [ 3 H]TdR incorporation occurred at 6 ϫ 10 5 cells/well ( Fig. 1 ). Higher cell density led to decreased proliferation over that observed at 6 ϫ 10 5 cells/well. Collectively, these data indicated that rd25 could induce significant cell proliferation in immunized mice under different experimental conditions.
Next, it was of interest to investigate whether splenocytes (5 ϫ 10 6 /ml) from rd25-immunized or C. neoformans-infected mice were able to release significant amounts of type 1 (IL-2 and IFN-␥) or type 2 (IL-4) cytokines. To measure the production of IL-2, IL-4, and IFN-␥, commercially available enzyme-linked immunosorbent assay kits (Euroclone, Wetherby, United Kingdom) were used, according to the manufacturer's instructions. The results reported in Fig. 2 show that a significant secretion of both IL-2 and IFN-␥ was observed in cultures of splenocytes from C. neoformans-infected or rd25-immunized mice after in vitro stimulation with the rd25 or with crude concentrated culture supernatants (CneF), obtained as previously described (2) . Maximal cytokine secretion was observed in splenocytes obtained at 14 days after immunization (Fig. 2) . As expected, splenocytes from PBS-injected mice were not able to induce type-1 cytokine release when stimulated with rd25 protein. No significant differences were detected between the rd25 and the nd25 protein in IL-2 and IFN-␥ secretion by FIG. 1. Proliferation of splenocytes from C. neoformans-infected (left) or rd25-immunized (right) mice after rd25 stimulation. Upper panels, spleens were collected at 14 days after immunization or infection, and splenocytes (6 ϫ 10 5 /well) were cultured for 72 h in the presence of various concentrations of rd25 before the addition of [ 3 H]TdR. Eighteen hours later the cells were collected onto filter paper, and the dried filters were counted in a liquid scintillation ␤-counter. Middle panels, spleens were collected at 14 days after immunization or infection, and various numbers of splenocytes were cultured in the presence of rd25 (10 g/ml). Lower panels, spleens were collected at 7, 14, and 28 days after immunization or infection, and splenocytes (6 ϫ 10 5 /well) were cultured in the presence of rd25 (10 g/ml). splenocytes (data not shown). When the supernatants from the experiments shown in Fig. 2 were tested for IL-4 concentration, no significant increases in the levels of this cytokine were observed under any of the experimental conditions used (not shown). CD4 ϩ T cells appear to be the main determinant of protection against disseminated cryptococcosis (8) . In order to assess which T-cell subset (CD4 ϩ or CD8 ϩ ) was responsible for d25-induced IFN-␥ and IL-2 production, CD4 ϩ and CD8 ϩ T cells were positively selected from spleen cells by means of a panning procedure using anti-murine CD4 ϩ and CD8 ϩ monoclonal antibodies, respectively (16) . These monoclonal antibodies were purified from GK 1.5 and 2.43 hybridomas (ATCC) (17) and coated on polystyrene tissue culture plates. CD4 ϩ and CD8 ϩ T cells were obtained as described previously (16) after first removing B cells from the cell suspension (5) . By immunofluorescence, Ͼ95% of the resulting cells were CD4 ϩ or CD8
ϩ . These cells (5 ϫ 10 6 /ml) were resuspended in complete RPMI and cultured in the presence of splenic adherent cells (5 ϫ 10 5 /ml) from normal mice (5). After stimulation with rd25 (10 g/ml), supernatants were harvested and assayed for IFN-␥ and IL-2 production. Levels of both cytokines were significantly elevated in rd25-stimulated, but not in unstimulated,
CD4
ϩ T cells from C. neoformans-infected mice (Fig. 3) . In addition, significant elevations of both cytokines were measured upon stimulation of CD4 ϩ cells with CneF. In contrast, CD8 ϩ T cells did not produce IFN-␥ or IL-2 at significant levels (Fig. 3 ). These data demonstrate that CD4 ϩ but not CD8 ϩ lymphocytes are the cell type responsible for increased type 1 cytokine production in response to rd25 stimulation.
Since IL-12 and tumor necrosis factor alpha (TNF-␣) have been reported to be essential for the development of protective T1 immunity to C. neoformans infection (4, 7, 9) , the effects of neutralization of these cytokines on d25-induced production of IFN-␥ and IL-2 were assessed. Mice were injected intraperitoneally (i.p.) with 0.2 mg of polyclonal goat anti-mouse TNF-␣ immunoglobulin G (IgG) (R&D Systems, distributed by Space Import Export, Milan, Italy), goat anti-mouse IL-12 IgG (17), or normal goat IgG at 1 h prior to immunization with rd25. IFN-␥ and IL-2 levels were measured in rd25-stimulated splenocyte cultures at 7 and 14 days after immunization. At both time points, IFN-␥ was significantly (P Ͻ 0.05) reduced in cultures from anti-TNF-␣-or anti-IL-12-treated mice, whereas the latter treatments did not affect production of IL-2 (Fig. 4) . These data indicated that both TNF-␣ and IL-12 were required for optimal IFN-␥, but not IL-2, production after rd25 immunization. Next, we determined whether the IL-2 and IFN-␥ responses observed after d25 immunization played a role in the protective effects of the latter. To assess the role of IL-2, groups of d25-immunized and nonimmunized mice were treated with polyclonal goat anti-mouse IL-2 IgG (R&D Systems) or normal goat IgG and challenged with C. neoformans (7.5 ϫ 10 3 CFU). Figure 5 shows that for nonimmunized animals treatment with anti-IL-2 IgG did not significantly affect survival time relative to that for normal IgG-treated controls (12.2 Ϯ 1.1 days versus 13.4 Ϯ 1.0 days; P ϭ 0.51). Similarly, in d25-immunized mice, anti-IL-2 treatment had no effects on survival time relative to that for normal IgG-treated controls (19.2 Ϯ 1.2 days versus 20.7 Ϯ 1.5 days; P ϭ 0.38) (Fig. 5A ). These data indicated that IL-2 production was not apparently required for the protective effects of d25 immunization. It is unlikely that the lack of effects of anti-IL-2 treatment we observed was due to insufficient in vivo IL-2 neutralization. In fact, mouse sera collected at 1, 2, and 4 weeks after anti-IL-2 treatment could totally neutralize, at 1:20 to 1:80 dilutions, the biological effects of recombinant IL-2. In these experiments, anti-IL-2 activity in mouse sera was detected by measuring inhibition of proliferation of CTLL-2 cell (ATCC) in the presence of 0.2 ng of rIL-2 (R&D Systems), exactly as described previously (6) .
Little is known of the role of IL-2 in C. neoformans infection. The addition of anti-IL-2 antibodies decreased the ability of human peripheral blood mononuclear cells to kill C. neoformans in vitro (20) . To our knowledge, the role of endogenous IL-2 has not been studied in experimental cryptococcosis. Our data suggest that at least under the experimental conditions we used, IL-2 blockade has no effect on C. neoformans-induced lethality. This may reflect the complex role of IL-2 as a T-cell growth factor capable of enhancing both Th1 and Th2 responses (23) . However, further studies are required to assess the role of IL-2 in anticryptococcal host defenses.
Next, we investigated the role of the IFN-␥ response in the protective effects of d25 immunization. Female IFN-␥ Ϫ/Ϫ (genetic background, C57BL/6) and their wild-type (WT) control mice (C57BL/6) were purchased from The Jackson Laboratory (Bar Harbor, Maine). IFN-␥-deficient mice were immunized with rd25 or PBS and challenged with C. neoformans (3 ϫ 10 4 CFU i.v.). Results were compared with those observed for identically treated wild-type mice. Figure 5B shows that, as expected (14) , nonimmunized IFN-␥-deficient mice succumbed more rapidly to C. neoformans infection than WT controls (P Ͻ 0.05). Moreover, the protective effects of d25 immunization observed in WT mice were totally abrogated in IFN-␥-deficient mice (Fig. 5B) . These data indicate that IFN-␥ has an obligatory role in the protective effects of d25 immunization.
In conclusion, our data show that the 25-kDa cryptococcal protein stimulates CD4 ϩ T cells to develop a protective Th1 response associated with increased IFN-␥ and IL-2 production. The IFN-␥ response, but not the IL-2 response, is apparently required for the protective effects of d25 immunization. There are considerable data to suggest that cell-mediated immunity in general, and T1 responses in particular, are important for host defenses against cryptococcosis (7, 9) . Results presented here indicate that d25 is the target for a CD4
ϩ -T-cell-mediated, IFN-␥-dependent protective immune response and support this antigen as a promising candidate for active or adoptive immunization strategies.
This work was supported by AIDS grants from the ISS ("Project AIDS" contract no. 50 C. 31 and 50 D. 30) and, in part, from MURST ("Progetti di Rilevanza Nazionale" contract no. 2001061479-006), CNR ("Progetto Finalizzato Biotecnologie"), and the European Commission ("HOSPATH" contract no. QLK2-CT-2000-00336).
